Cardiol Therapeutics Inc Class A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for … Read more
Cardiol Therapeutics Inc Class A (CRDL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.724x
Based on the latest financial reports, Cardiol Therapeutics Inc Class A (CRDL) has a cash flow conversion efficiency ratio of -0.724x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.93 Million) by net assets ($9.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cardiol Therapeutics Inc Class A - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Cardiol Therapeutics Inc Class A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cardiol Therapeutics Inc Class A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cardiol Therapeutics Inc Class A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alpha Cognition Inc
NASDAQ:ACOG
|
-0.158x |
|
Kenilworth Systems C
PINK:KENS
|
2.767x |
|
Dusit Thani Public Company Limited
BK:DUSIT
|
0.122x |
|
NanoenTekInc
KQ:039860
|
0.031x |
|
Currenc Group Inc. Ordinary Shares
NASDAQ:CURR
|
-0.355x |
|
Sutro Biopharma
NASDAQ:STRO
|
0.438x |
|
Mercer International Inc
NASDAQ:MERC
|
0.678x |
|
American Lithium Corp. Common Stock
NASDAQ:AMLI
|
-0.019x |
Annual Cash Flow Conversion Efficiency for Cardiol Therapeutics Inc Class A (2017–2024)
The table below shows the annual cash flow conversion efficiency of Cardiol Therapeutics Inc Class A from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $24.73 Million | $-25.06 Million | -1.013x | -13.68% |
| 2023-12-31 | $28.25 Million | $-25.18 Million | -0.891x | -26.12% |
| 2022-12-31 | $38.51 Million | $-27.22 Million | -0.707x | -128.82% |
| 2021-12-31 | $76.24 Million | $-23.55 Million | -0.309x | +55.10% |
| 2020-12-31 | $13.27 Million | $-9.13 Million | -0.688x | +11.30% |
| 2019-12-31 | $14.67 Million | $-11.38 Million | -0.776x | -58.59% |
| 2018-12-31 | $22.27 Million | $-10.89 Million | -0.489x | -8.02% |
| 2017-12-31 | $2.85 Million | $-1.29 Million | -0.453x | -- |